What Is Retatrutide? A Comprehensive Overview of LY3437943

Introduction

Retatrutide, known by its development code LY3437943, is an investigational peptide therapeutic that represents a new frontier in metabolic medicine. Developed by Eli Lilly and Company, retatrutide is the first molecule in clinical development to simultaneously activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This triple receptor agonism distinguishes retatrutide from currently approved therapies and has generated considerable scientific interest based on striking results from its Phase 2 clinical program.

The development of retatrutide reflects a broader evolution in metabolic therapeutics. Over the past two decades, the field has progressed from single-target approaches, such as GLP-1 receptor agonists like semaglutide and liraglutide, to multi-target strategies. Tirzepatide, also from Eli Lilly, demonstrated the power of dual GIP/GLP-1 receptor agonism and received FDA approval for type 2 diabetes (as Mounjaro) and obesity (as Zepbound). Retatrutide takes the next logical step by adding glucagon receptor activation to the existing dual agonist framework.

Development Code and Nomenclature

Retatrutide carries the Eli Lilly development code LY3437943. The compound received its International Nonproprietary Name (INN) of “retatrutide” from the World Health Organization, following the naming convention for incretin-based peptides. The “-trutide” suffix indicates its membership in the class of multi-receptor agonist peptides related to the GIP/GLP-1/glucagon hormone family, similar to how tirzepatide’s “-tide” suffix reflects its peptide nature.

It is important to note that retatrutide does not yet have a brand name, as it has not received marketing authorization from any regulatory agency. References to retatrutide in the scientific literature may use either the INN or the LY3437943 designation, depending on the publication date and context.

The Triple Agonist Concept

The core innovation of retatrutide lies in its simultaneous engagement of three receptor systems, each contributing distinct physiological effects:

GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that enhances glucose-dependent insulin secretion and has emerging roles in fat tissue regulation and central appetite control. Retatrutide exhibits its highest potency at the GIP receptor, which is notable given that GIP receptor agonism has become increasingly recognized as a meaningful contributor to metabolic improvement. The success of tirzepatide validated the principle that GIP agonism, when combined with GLP-1 receptor activation, can enhance weight loss and glycemic control beyond what GLP-1 agonism alone achieves.

GLP-1 Receptor Agonism

GLP-1 receptor activation is the most extensively validated mechanism in modern metabolic therapeutics. GLP-1 receptor agonists reduce appetite through central nervous system effects, improve glycemic control through glucose-dependent insulin secretion and glucagon suppression, and slow gastric emptying. In retatrutide, GLP-1 receptor agonism provides the foundational metabolic benefits that have made this pathway the backbone of obesity and diabetes pharmacotherapy.

Glucagon Receptor Agonism

The inclusion of glucagon receptor agonism is what makes retatrutide truly novel. Glucagon, traditionally viewed only as a counter-regulatory hormone that raises blood sugar, has significant effects on energy expenditure and hepatic lipid metabolism. Glucagon receptor activation increases resting energy expenditure and promotes fatty acid oxidation in the liver, contributing to calorie burning and liver fat reduction. The concern that glucagon’s glucose-raising effects would undermine glycemic control has been addressed by the concurrent GLP-1 and GIP receptor agonism, which provide sufficient glucose-lowering activity to offset this effect.

Why Retatrutide Matters

Unprecedented Weight Loss in Phase 2

The Phase 2 obesity trial, published in the New England Journal of Medicine in 2023 by Jastreboff and colleagues, produced results that captured widespread attention in the scientific and medical communities. In this 48-week, randomized, double-blind, placebo-controlled trial of 338 adults with obesity, the highest-dose group (12 mg) achieved a mean body weight reduction of 24.2% from baseline. This level of weight loss had not been previously reported for any pharmacological agent in a rigorous clinical trial setting and approaches the results typically associated with bariatric surgery.

Robust Glycemic Control

In the Phase 2 type 2 diabetes trial, published in The Lancet in 2023 by Rosenstock and colleagues, retatrutide demonstrated potent HbA1c reductions of up to 2.02 percentage points. A majority of participants in the higher-dose groups achieved HbA1c levels below 7.0%, and a notable proportion reached levels below 5.7%, which is considered the non-diabetic range. These results suggest that retatrutide’s triple mechanism provides glycemic efficacy that is competitive with or exceeds existing therapies.

Liver Fat Reduction

One of the most compelling secondary findings from the clinical program was a marked reduction in liver fat content. In the obesity trial, participants in the highest-dose group experienced an average relative reduction in liver fat of approximately 82% from baseline. Given the growing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), this hepatic effect, likely driven by the glucagon receptor component, represents a potentially significant therapeutic benefit.

Metabolic Breadth

Beyond weight and glucose, retatrutide demonstrated improvements across a range of cardiometabolic parameters, including reductions in triglycerides, improvements in blood pressure, and favorable changes in waist circumference and body composition. The breadth of metabolic effects seen in Phase 2 data suggests that triple agonism addresses the multifactorial nature of metabolic disease more comprehensively than single- or dual-target approaches.

Molecular Design

Retatrutide is a 39-amino-acid peptide that was engineered by Eli Lilly researchers to achieve balanced activity across all three target receptors. The molecule is based on a modified GIP peptide backbone, with specific amino acid substitutions and modifications to confer GLP-1 and glucagon receptor activity. A C20 fatty diacid moiety is conjugated to the peptide via a linker, facilitating binding to serum albumin. This albumin binding extends the molecule’s circulatory half-life to approximately six days, enabling once-weekly subcutaneous administration.

The structural design of retatrutide leverages the evolutionary relationship among the GIP, GLP-1, and glucagon peptide families, all of which belong to the glucagon superfamily and share significant sequence homology. This shared ancestry made it feasible, though technically challenging, to construct a single peptide that engages all three receptor types with therapeutically relevant potency.

Current Development Status

As of early 2025, retatrutide is in Phase 3 clinical development. The Phase 3 program, designated TRIUMPH (Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health), includes multiple large-scale pivotal trials:

• TRIUMPH-1: Evaluating retatrutide in adults with obesity or overweight with weight-related comorbidities
• TRIUMPH-2: Evaluating retatrutide in adults with type 2 diabetes and obesity or overweight

These trials are enrolling thousands of participants across global clinical sites and are expected to generate the definitive efficacy and safety data required for regulatory submissions. Eli Lilly has indicated that regulatory filings could begin following the completion and analysis of these pivotal trials.

Context Within the Therapeutic Landscape

Retatrutide enters a rapidly evolving therapeutic landscape. The GLP-1 receptor agonist class has experienced remarkable commercial and clinical success, with semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) transforming the treatment of obesity and diabetes. However, several unmet needs remain:

• Greater magnitude of weight loss: While current therapies produce clinically meaningful weight loss, many patients do not achieve the degree of weight reduction associated with sustained metabolic health improvement.
• Liver disease treatment: No pharmacological therapy is broadly approved for MASLD, and the liver fat reduction observed with retatrutide’s glucagon component may address this gap.
• Comprehensive metabolic improvement: The multifactorial nature of metabolic syndrome suggests that multi-target approaches may provide broader benefits than single-receptor therapies.

Safety Considerations

The Phase 2 data established that retatrutide’s safety profile is broadly consistent with the known effects of incretin-based therapies. Gastrointestinal adverse events, including nausea, diarrhea, vomiting, and constipation, were the most commonly reported side effects and were predominantly mild to moderate in severity. Most gastrointestinal events occurred during dose-escalation periods and diminished over time. Treatment discontinuation rates due to adverse events were dose-dependent but remained within the range observed for other agents in this class.

Importantly, no unexpected safety signals emerged from the Phase 2 program. However, the relatively small sample sizes of Phase 2 trials limit the ability to detect uncommon adverse events, and the ongoing Phase 3 TRIUMPH program, with its larger and more diverse participant populations, will provide a more comprehensive safety assessment.

Looking Ahead

Retatrutide represents a compelling step forward in the evolution of metabolic therapeutics. Its triple receptor mechanism, unprecedented Phase 2 weight loss data, and broad metabolic effects have positioned it as one of the most closely watched investigational compounds in endocrinology and obesity medicine. The Phase 3 TRIUMPH program will determine whether the promise of Phase 2 translates into a consistent, reproducible benefit profile suitable for regulatory approval and widespread clinical use.

The scientific community awaits the TRIUMPH results with considerable interest, recognizing that confirmation of the Phase 2 findings could establish triple receptor agonism as a new paradigm in the treatment of obesity and its metabolic complications.